 |
BioWorld-International-2011-05-25
Membrane Receptors Will Open Door to Drug Discovery
GenKyoTex's $20.4M Series C Funds NOX Inhibitor Progress
LONDON – GenKyoTex SA raised CHF18 million (US$20.4 million) in a Series C round, enabling it to take the lead product to the point where it is ready to deliver proof of concept for the company's NOX enzyme inhibition technology. (BioWorld International)